The GLP-1 receptor agonists are the biggest group: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are approved for type 2 diabetes and obesity on the strength of large trials, and are compared head-to-head in the published literature
Dosing tends toward the higher end of the standard range, often 0.5 mg daily throughout the treatment period
Among all Part D plans, median standard cost sharing in 2025 for different types of drugs is (Figure 10): Generics : $0 for preferred generics and $5 for other generics in both PDPs and MA-PDs
When tirzepatide was in Phase 3 trials (2020-2022), Lilly similarly did not disclose the KwikPen format ahead of approval
A pilot study on the effects of l-Carnitine and Trimethylamine-N-oxide on platelet mitochondrial DNA methylation and CVD biomarkers in aged women
Breaks down up to 22g of fat per capsule*